649 – Effects of sodium glucose cotransporter-2 inhibitors on circulating stem and progenitor cells in patients with type 2 diabetes – B. Bonora, R. Cappellari, A. Avogaro, G. Fadini, Italy

650 – Dapagliflozin preserves renal vasodilating capacity in hypertensive patients with type 2 diabetes – R. Bruno, L. Giannini, A. Dardano, E. Biancalana, M. Seghieri, S. Taddei, L. Ghiadoni, A. Solini, Italy

651 – Small increases in serum magnesium levels by dapagliflozin and normalisation of hypomagnesaemia in patients with type 2 diabetes – R. Toto, R. Goldenberg, G.M. Chertow, V. Cain, B.V. Stefansson, C.D. Sjöström, P. Sartipy, USA, Canada, Sweden

652 – SGLT-2 inhibitors efficacy in type 2 diabetic patients with bariatric surgery – J.P. Valderas, Y. Preiss, M. Sepulveda, F. Crovari, C. Boza, Chile

653 – Effects of dapagliflozin on urine and plasma metabolome in patients with type 2 diabetes: preliminary results – V. Tsimihodimos, E. Ferrannini, S. Filippas-Dekouan, E. Bletsa, A. Dimou, E. Bairaktari, M. Elisaf, Greece, Italy

654 – Effects of SGLT2 inhibitors in cells (human myeloid angiogenic cells and platelets) pivotally involved in atherosclerotic plaque (in)stability/thrombosis – V. Spigoni, F. Fantuzzi, C. Carubbi, G. Pozzi, E. Masselli, D. Galli, G. Gobbi, P. Mirandola, M. Vitale, R.C. Bonadonna, A. Dei Cas, Italy

655 – Determinants of the improved arterial stiffness observed after empagliflozin treatment – R.E. Schmieder, A. Bosch, S. Jung, K. Striepe, M.V. Karg, D. Kannenkeril, T. Dienemann, C. Ott, Germany

656 – SGLT2 inhibitors effect on fatty liver disease in patients with Berardinelli-Seip lipodystrophy – E.B. Parente, V.R. Simoes, M.A. Medeiros, I.E. Bacha, E.R. Parisi, J.E. Salles, Brazil

657 – Dapagliflozin improves liver dysfunction in parallel with a decrease in serum soluble DPP-4/CD26 level in type 2 diabetic patients with non-alcoholic fatty liver – H. Kishi, K. Suzuki, K. Kato, M. Shimizu, T. Jojima, T. Iijima, I. Usui, Y. Aso, Japan

658 – Canagliflozin prevents development of hepatocellular carcinoma (HCC) from non-alcoholic steatohepatitis (NASH) in a novel mouse model of NASH-HCC under diabetic state – T. Jojima, H. Kishi, T. Iijima, I. Usui, Y. Aso, Japan